CD274 and non-small cell lung carcinoma: Monotherapy with checkpoint antibodies have not been explored fully as only 27 patients were included in the trial [1] and perhaps stratifying patients to include patients with high PDL1 expression may be beneficial as was seen in patients with NSCLC [32].